USPTO serial 79305348
OMGEVI
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Jan 25, 2022
- Examiner
- JAGANNATHAN, SIDDHARTH
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with OMGEVI?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Theravance Biopharma Ireland Limited
IE
Other trademarks owned by Theravance Biopharma Ireland Limited
Theravance Biopharma Ireland Limited
IE
Other trademarks owned by Theravance Biopharma Ireland Limited
Theravance Biopharma Ireland Limited
IE
Other trademarks owned by Theravance Biopharma Ireland Limited
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Beth H. Alter
Beth H. Alter Seward & Kissel LLPOne Battery Park PlazaNew York, NY 10004UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Diagnostic preparations and materials, namely, diagnostic preparations for medical and veterinary use; pharmaceutical preparations for treatment of human diseases of the autonomic, respiratory, endocrine, circulatory, gastrointestinal, genito-urinary, integumentary, immune and central nervous system; pharmaceutical preparations for the treatment of cancer and pain; pharmaceutical preparations and substances for the treatment of respiratory diseases and disorders; pharmaceutical preparations and substances for the treatment of gastrointestinal diseases and disorders; pharmaceutical preparations and substances for the treatment of ocular and dermatological diseases and disorders; pharmaceutical preparations and substances for the treatment of neurogenic orthostatic hypotension and for the prevention and treatment of low blood pressure; pharmaceutical preparations and substances in the nature of anti-hypotensive and vasopressor agents; pharmaceutical preparations and substances for the treatment of Parkinson's disease and disorders; pharmaceutical preparations and substances for the prevention and treatment of dizziness and lightheadedness; pharmaceutical preparations and substances for the treatment of disorders characterized by a deficiency of norepinephrine; pharmaceutical preparations and substances for the treatment of bacterial and viral infections, namely anti-infectives | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Theravance Biopharma Ireland Limited
- Other trademarks owned by Theravance Biopharma Ireland Limited
- Other trademarks owned by Theravance Biopharma Ireland Limited
- Other trademarks in Class 005
- Similar marks named OMGEVI
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jul 23, 2023 | ADCH | CHANGE OF NAME/ADDRESS REC'D FROM IB | — |
| Aug 1, 2022 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Jul 7, 2022 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Jul 7, 2022 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Apr 25, 2022 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Jan 25, 2022 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Nov 9, 2021 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Nov 9, 2021 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Oct 20, 2021 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Oct 4, 2021 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Oct 1, 2021 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Oct 1, 2021 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Oct 1, 2021 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Aug 15, 2021 | RFNT | REFUSAL PROCESSED BY IB | — |
| Jul 28, 2021 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Jul 28, 2021 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Jul 19, 2021 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Jul 18, 2021 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jul 3, 2021 | DOCK | ASSIGNED TO EXAMINER | — |
| Mar 9, 2021 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Mar 5, 2021 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Mar 4, 2021 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |